collagen type I trimeric cross-linked peptide

contains trifunctional cross-linking amino acid pyridinoline; marker for alveolar bone loss; amino acid sequence & structure in first source
Also Known As:
C-telopeptide; C-terminal type I collagen telopeptide; CTCLP; CTx telopeptide; N-telopeptide; N-terminal type I collagen telopeptide; NTx telopeptide; i-ICTP; pyridinoline cross-linked carboxy-terminal telopeptide, collagen type I; serum ICTP; serum carboxyterminal telopeptide type I collagen; trimeric cross-linked peptide collagen type I
Networked: 624 relevant articles (12 outcomes, 65 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lipton, Allan: 12 articles (09/2015 - 02/2002)
2. Garnero, P: 12 articles (03/2009 - 02/2000)
3. Delmas, P D: 10 articles (10/2003 - 01/2000)
4. Coleman, Robert E: 8 articles (03/2010 - 05/2002)
5. Fizazi, Karim: 7 articles (09/2015 - 04/2009)
6. Saad, Fred: 7 articles (09/2015 - 01/2005)
7. Eastell, Richard: 7 articles (12/2014 - 01/2003)
8. Terpos, Evangelos: 7 articles (01/2014 - 09/2004)
9. Christgau, S: 7 articles (03/2009 - 05/2001)
10. Inaba, Masaaki: 6 articles (03/2015 - 01/2004)

Related Diseases

1. Bone Resorption
2. Neoplasm Metastasis (Metastasis)
3. Osteoporosis
4. Postmenopausal Osteoporosis
04/01/2000 - "These findings and the values of serum ICTP, PICP and BGP in pre- and postmenopausal women obtained in this study are expected to be very useful for treatment of postmenopausal osteoporosis."
01/01/2012 - "Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate."
01/01/1994 - "We conclude that serum ICTP does reflect bone metabolism in postmenopausal osteoporosis, but it is not a sensitive marker of the changes in bone resorption induced by hormone replacement therapy, and it does not correspond with other measures of bone resorption during anabolic steroid therapy."
12/01/2004 - "Using selected data from clinical studies involving 174 women with postmenopausal osteoporosis (PMO), a classical multicompartmental pharmacokinetic-pharmacodynamic (PK-PD) model was developed that accurately described the PK of i.v. ibandronate in plasma and urine and urinary excretion of the C-telopeptide of the alpha chain of type I collagen (uCTX), a sensitive biomarker of PD response to ibandronate. "
07/01/2003 - "In the Danish cohort (n = 306) of the Early Postmenopausal Intervention Cohort (EPIC) Study (n = 1609) of oral alendronate (ALN) for prevention of postmenopausal osteoporosis, bone markers (urine C-telopeptides of type I collagen (uCTX), urine N-telopeptide cross-links of type I collagen (uNTX), serum total osteocalcin measured by ELISA [total OC (ELISA)], and serum total osteocalcin measured by RIA [total OC (RIA)]) were measured at 6-month intervals. "
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. collagen type I trimeric cross-linked peptide
2. Collagen Type I (Type I Collagen)
3. Collagen
4. Osteocalcin
5. Alkaline Phosphatase
6. Biological Markers (Surrogate Marker)
7. deoxypyridinoline
8. Alendronate (Alendronate Sodium)
9. Calcium
10. Diphosphonates

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Hormone Replacement Therapy (Therapy, Hormone Replacement)
3. Microspheres (Microsphere)
4. Aftercare (After-Treatment)
5. Ovariectomy (Oophorectomy)